Kikuchi Kiyoshi, Takeshige Nobuyuki, Miura Naoki, Morimoto Yoko, Ito Takashi, Tancharoen Salunya, Miyata Kei, Kikuchi Chiemi, Iida Narumi, Uchikado Hisaaki, Miyagi Naohisa, Shiomi Naoto, Kuramoto Terukazu, Maruyama Ikuro, Morioka Motohiro, Kawahara Ko-Ichi
Department of Neurosurgery, Yame Public General Hospital, Yame 834-0034;
Exp Ther Med. 2012 Jan;3(1):3-8. doi: 10.3892/etm.2011.352. Epub 2011 Sep 20.
Free radicals play an important role in the pathogenesis of a variety of diseases; thus, they are an attractive target for therapeutic intervention in these diseases. Compounds capable of scavenging free radicals have been developed for this purpose and some, developed for the treatment of cerebral ischemic stroke, have progressed to clinical trials. One such scavenger, edaravone, is used to treat patients within 24 h of stroke. Edaravone, which can diffuse into many disease-affected organs, also shows protective effects in the heart, lung, intestine, liver, pancreas, kidney, bladder and testis. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic and anti-cytokine effects in various diseases. Here, we critically review the literature on its clinical efficacy and examine whether edaravone should be considered a candidate for worldwide development, focusing on its effects on diseases other than cerebral infarction. Edaravone has been safely used as a free radical scavenger for more than 10 years; we propose that edaravone may offer a novel treatment option for several diseases.
自由基在多种疾病的发病机制中起着重要作用；因此，它们是这些疾病治疗干预的一个有吸引力的靶点。为此，已经开发出了能够清除自由基的化合物，其中一些用于治疗脑缺血性中风的化合物已经进入临床试验阶段。一种这样的清除剂依达拉奉，用于在中风后24小时内治疗患者。依达拉奉能够扩散到许多受疾病影响的器官，在心脏、肺、肠道、肝脏、胰腺、肾脏、膀胱和睾丸中也显示出保护作用。除了清除自由基外，依达拉奉在各种疾病中还具有抗凋亡、抗坏死和抗细胞因子的作用。在此，我们批判性地回顾了关于其临床疗效的文献，并探讨依达拉奉是否应被视为全球开发的候选药物，重点关注其对脑梗死以外疾病的影响。依达拉奉作为自由基清除剂已安全使用了10多年；我们认为依达拉奉可能为几种疾病提供一种新的治疗选择。
